Behavioral economic and wellness-based approaches for reducing alcohol use and consequences among diverse non-student emerging adults: study protocol for Project BLUE, a randomized controlled trial.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
09 Mar 2024
Historique:
received: 12 12 2023
accepted: 22 02 2024
medline: 11 3 2024
pubmed: 9 3 2024
entrez: 8 3 2024
Statut: epublish

Résumé

Emerging adults (EAs) who are not 4-year college students nor graduates are at elevated risk for lifetime alcohol use disorder, comorbid drug use, and mental health symptoms, compared to college graduates. There is a need for tailored brief alcohol intervention (BAI) approaches to reduce alcohol risk and to facilitate healthy development in this high-risk population. Most BAIs include a single session focused on discussing risks associated with drinking and correcting normative beliefs about drinking rates. EAs may benefit from additional elements that enhance general wellness. The substance-free activity session (SFAS) aims to clarify life goals and values and increase goal-directed activities that provide alternatives to alcohol use, and the relaxation training (RT) session teaches relaxation and stress reduction skills. The present study is a randomized 3-group (BAI + SFAS vs. RT + SFAS vs. education control) trial with 525 EAs (175 per group; estimated 50% women and 50% African American) who report recent risky drinking and who are not students or graduates of 4-year colleges. Participants will have the option of completing the intervention sessions in person or via a secure video teleconference. Levels of drinking and alcohol-related problems will be evaluated at baseline and 1, 3, 6, and 12 months post-intervention. The primary hypothesis is that both BAI + SFAS and RT + SFAS participants will report significantly greater reductions in alcohol use and problems relative to education control participants, with no differences in outcomes between the two active treatment conditions. The results of this study will inform alcohol prevention efforts for high-risk community dwelling emerging adults. ClinicalTrials.gov Identifier: NCT04776278.

Sections du résumé

BACKGROUND BACKGROUND
Emerging adults (EAs) who are not 4-year college students nor graduates are at elevated risk for lifetime alcohol use disorder, comorbid drug use, and mental health symptoms, compared to college graduates. There is a need for tailored brief alcohol intervention (BAI) approaches to reduce alcohol risk and to facilitate healthy development in this high-risk population. Most BAIs include a single session focused on discussing risks associated with drinking and correcting normative beliefs about drinking rates. EAs may benefit from additional elements that enhance general wellness. The substance-free activity session (SFAS) aims to clarify life goals and values and increase goal-directed activities that provide alternatives to alcohol use, and the relaxation training (RT) session teaches relaxation and stress reduction skills.
METHODS METHODS
The present study is a randomized 3-group (BAI + SFAS vs. RT + SFAS vs. education control) trial with 525 EAs (175 per group; estimated 50% women and 50% African American) who report recent risky drinking and who are not students or graduates of 4-year colleges. Participants will have the option of completing the intervention sessions in person or via a secure video teleconference. Levels of drinking and alcohol-related problems will be evaluated at baseline and 1, 3, 6, and 12 months post-intervention. The primary hypothesis is that both BAI + SFAS and RT + SFAS participants will report significantly greater reductions in alcohol use and problems relative to education control participants, with no differences in outcomes between the two active treatment conditions.
DISCUSSION CONCLUSIONS
The results of this study will inform alcohol prevention efforts for high-risk community dwelling emerging adults.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov Identifier: NCT04776278.

Identifiants

pubmed: 38459579
doi: 10.1186/s13063-024-08009-9
pii: 10.1186/s13063-024-08009-9
pmc: PMC10924404
doi:

Banques de données

ClinicalTrials.gov
['NCT04776278']

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

173

Subventions

Organisme : NIAAA NIH HHS
ID : R01 AA029031
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

© 2024. The Author(s).

Références

J Consult Clin Psychol. 2017 May;85(5):447-458
pubmed: 28287800
Behav Res Methods. 2011 Sep;43(3):692-700
pubmed: 21487904
BMJ. 2018 Jul 18;362:k2817
pubmed: 30021785
Alcohol Clin Exp Res. 2021 Oct;45(10):2147-2159
pubmed: 34342015
Br J Clin Pharmacol. 2017 Aug;83(8):1636-1642
pubmed: 28252213
Psychol Addict Behav. 2022 Sep;36(6):664-677
pubmed: 34914406
J Consult Clin Psychol. 2007 Aug;75(4):663-9
pubmed: 17663621
Exp Clin Psychopharmacol. 2005 May;13(2):93-101
pubmed: 15943542
J Consult Clin Psychol. 2019 Jul;87(7):657-669
pubmed: 31070386
J Stud Alcohol Drugs. 2011 Jul;72(4):622-32
pubmed: 21683044
Alcohol Clin Exp Res. 2018 Apr;42(4):781-794
pubmed: 29485676
J Stud Alcohol. 2005 Sep;66(5):698-705
pubmed: 16329461
Alcohol Clin Exp Res. 2015 May;39(5):919-31
pubmed: 25872599
Brookings Pap Econ Act. 2017 Spring;2017:397-476
pubmed: 29033460
Psychol Rev. 2008 Jan;115(1):186-98
pubmed: 18211190
Psychol Addict Behav. 2023 May;37(3):462-474
pubmed: 35482647
Int J Behav Med. 1997;4(1):92-100
pubmed: 16250744
Exp Clin Psychopharmacol. 2009 Dec;17(6):396-404
pubmed: 19968404
Prev Sci. 2023 Nov;24(8):1608-1621
pubmed: 35976524
Am J Psychiatry. 2013 Aug;170(8):834-51
pubmed: 23903334
Psychol Addict Behav. 2022 Sep;36(6):573-580
pubmed: 36066870
Drug Alcohol Depend. 2008 May 1;95(1-2):169-72
pubmed: 18243583
Behav Res Ther. 1995 Mar;33(3):335-43
pubmed: 7726811
J Youth Adolesc. 2015 Oct;44(10):1884-97
pubmed: 26036995
J Adv Pharm Technol Res. 2016 Oct-Dec;7(4):118-122
pubmed: 27833889
J Consult Clin Psychol. 2000 Oct;68(5):898-908
pubmed: 11068976
Alcohol Clin Exp Res. 2005 Jul;29(7):1180-9
pubmed: 16046873
J Consult Clin Psychol. 2012 Oct;80(5):876-86
pubmed: 22663899
Psychol Addict Behav. 2022 Mar;36(2):157-176
pubmed: 33749290
J Subst Abuse Treat. 2020 Jun;113:108002
pubmed: 32359674
Alcohol Clin Exp Res. 2018 Jul;42(7):1342-1351
pubmed: 29750362
Addict Behav. 2018 Apr;79:107-112
pubmed: 29287186
J Gen Intern Med. 2011 Feb;26(2):192-6
pubmed: 20857339
J Med Internet Res. 2020 Aug 11;22(8):e17449
pubmed: 32780027
Annu Rev Public Health. 2009;30:341-55
pubmed: 19705561
Psychol Addict Behav. 2017 May;31(3):242-254
pubmed: 28318279
Alcohol Clin Exp Res. 2020 Jan;44(1):178-187
pubmed: 31912524
Curr Addict Rep. 2015 Mar;2(1):47-57
pubmed: 26258001
J Stud Alcohol Drugs. 2017 Jul;78(4):540-548
pubmed: 28728636
J Consult Clin Psychol. 1985 Apr;53(2):189-200
pubmed: 3998247
J Am Acad Child Adolesc Psychiatry. 2010 Dec;49(12):1189-201; quiz 1285
pubmed: 21093769
Rehabil Psychol. 2011 Nov;56(4):267-88
pubmed: 21967118
Psychol Addict Behav. 2023 Jun 29;:
pubmed: 37384451
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
JAMA Psychiatry. 2017 Sep 1;74(9):911-923
pubmed: 28793133
Clin Psychol Rev. 2019 Jun;70:79-90
pubmed: 30991244
J Law Med Ethics. 2018 Jun;46(2):404-421
pubmed: 30146996
Exp Clin Psychopharmacol. 2018 Aug;26(4):347-353
pubmed: 29952619
Psychol Methods. 2002 Mar;7(1):83-104
pubmed: 11928892
Ann Intern Med. 2006 Jul 4;145(1):62-9
pubmed: 16818930
Mol Psychiatry. 2021 Apr;26(4):1119-1132
pubmed: 31649322
Psychol Addict Behav. 2010 Dec;24(4):571-80
pubmed: 21198220
Subst Use Misuse. 2019;54(1):31-38
pubmed: 29963933
Psychol Addict Behav. 2022 Sep;36(6):607-618
pubmed: 35084904

Auteurs

James G Murphy (JG)

Department of Psychology, The University of Memphis, 400 Innovation Dr, Memphis, TN, 38152, USA. jgmurphy@memphis.edu.

Ashley A Dennhardt (AA)

Department of Psychology, The University of Memphis, 400 Innovation Dr, Memphis, TN, 38152, USA.

Jacob Tempchin (J)

Department of Psychology, The University of Memphis, 400 Innovation Dr, Memphis, TN, 38152, USA.

Hannah E Colgonis (HE)

Department of Psychology, The University of Memphis, 400 Innovation Dr, Memphis, TN, 38152, USA.

Meghan E McDevitt-Murphy (ME)

Department of Psychology, The University of Memphis, 400 Innovation Dr, Memphis, TN, 38152, USA.

Brian Borsari (B)

Mental Health Service (116B), San Francisco VAHCS, San Francisco, CA, USA.
Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA, USA.

Kristoffer S Berlin (KS)

Department of Psychology, The University of Memphis, 400 Innovation Dr, Memphis, TN, 38152, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH